ALL maintenance treatment: coordinating monitoring across countries
Maintenance treatment for ALL is still active treatment. Moving between countries during this phase requires an agreed prescribing and monitoring plan, even if much of the care takes place outside hospital. The practical risk is not only running out of medicine; it is having results, prescriptions and responsibility separated between teams that are not communicating.
Use one current version of the prescription
ALL programmes may include a prolonged maintenance phase. Its medicines and monitoring depend on the actual protocol. Keep a dated prescription showing what is currently intended, together with written changes from the treating team. Do not use the first discharge list indefinitely if later instructions have changed.
If medicines are taken on different days, ask for an unambiguous calendar prepared or confirmed by the clinical team. It should distinguish regular treatment from a temporary instruction. A translated calendar can help, but it must preserve medicine names, strength and the prescriber’s directions exactly. Family members should not simplify it by guessing that two similarly named products are equivalent.
Decide who acts on each result
Having blood collected is only one part of monitoring. Before a visit abroad, identify the laboratory, the doctor who will review the result and the route for receiving any instruction. Agree what to do if a result is delayed or the usual clinician is unavailable. “Send us the blood test” is incomplete unless responsibility for checking it is clear.
The prescribing team should specify which tests are needed and when. Do not change treatment in response to a value highlighted by a laboratory portal without the agreed clinical advice. Equally, a reassuring result does not give permission to alter the plan or postpone the next scheduled review.
Report difficulties without trying to fix the schedule yourself
If a dose is missed, vomiting occurs after a medicine or instructions have become unclear, contact the team for the situation-specific advice. Do not make up for an uncertain dose on your own. Write down what happened and when; a precise account is more useful than hiding the problem or trying to recreate the ideal calendar afterwards.
Tell the clinician about new prescriptions, over-the-counter products and supplements. If tolerability or access is making the regimen difficult, raise that before a journey. The aim is a plan the patient can follow safely, with professional changes when needed, rather than an appearance of perfect adherence in the record.
Prepare supply and urgent care together
For travel to Turkey, confirm how the prescribed medicines will be obtained and what documentation the responsible hospital and pharmacy need. Ask the treating team how much flexibility the plan allows if the return date changes. Do not rely on finding an identical brand after arrival, and do not assume that an online price establishes lawful supply or clinical suitability.
Our guide to planning prescribed medicines for a medical journey helps organise supply questions. Carry the agreed urgent-care instructions and the current treatment summary in an accessible form. A new fever or serious illness requires prompt contact through the treatment team’s emergency pathway; the next routine monitoring appointment is not the place to wait for that assessment.
When returning home, pass on any new results, prescription changes and care received abroad. Ask the original team to confirm the next version of the plan. A successful handover ends with one clear account of what happens next, rather than two sets of instructions that the patient must reconcile alone.
Sources
Medicina Turkey patient information. General guidance; individual medical decisions should be discussed with the treating clinician.